Type 2 diabetes and metabolism studies

Type 2 diabetes in childhood: national cohort (JUMP)

Investigator:

T Barrett t.g.barrett@bham.ac.uk

Sponsor:

University of Birmingham

Summary:

This is a UK national, prospective, cohort study of children and young people with type 2 diabetes (T2D) characterised by anthropometry, biomarkers, and co-morbidities; and in whom other diagnoses (such as type 1 diabetes, maturity onset diabetes of the young (MODY)) have been excluded. The overall objective of this study is to characterise a cohort of children and young people with T2D. This will include baseline and repeat assessments over time of the anthropometric, cardiovascular, metabolic and psychological status of individuals with T2D in order to describe the natural history of T2D and related co-morbidities in a multiethnic cohort of UK children with the disease.  

Start Date:

End Date:

Further Information:

 

A Phase III, Multicenter, Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-0431A (A Fixed-Dose Combination Tablet of Sitagliptin and Metformin) in Pediatric Patients with Type 2 Diabetes Mellitus

Investigator:

T Barrett t.g.barrett@bham.ac.uk

Sponsor:

Merck

Summary:

This study is designed to assess the safety and efficacy of sitagliptin added to ongoing metformin therapy compared with the addition of placebo to ongoing metformin therapy for the treatment of T2DM in pediatric patients (10-17 years of age, inclusive) with inadequate glycemic control on metformin monotherapy. This is a multinational, placebo controlled, double-blind, parallel-group study of approximately 22 weeks duration, including a screening period of 1 week, a 1-week single-blind placebo run-in period, and a 20-week placebo-controlled, double-blind treatment period [Visits 3 to 9]

Start Date:

End Date:

Further Information:

 

A 26 Week, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Phase 3 Trial with a 26 Week Safety Extension Period Evaluating the Safety and Efficacy of Dapagliflozin 5 and 10 mg, and Saxagliptin 2.5 and 5 mg in Pediatric Patients with Type 2 Diabetes Mellitus who are between 10 and below 18 Years of Age

Investigator:

T Barrett t.g.barrett@bham.ac.uk

Sponsor:

Astra Zeneca

Summary:

The purpose of this research study is to evaluate the effectiveness and safety of dapagliflozin and saxagliptin in patients with Type 2 Diabetes who are aged 10 to below 18 years old and are currently taking metformin, insulin, or both medicines.

Start Date:

End Date:

Further Information: